Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ...

Invikafusp alfa demonstrated significant antitumor activity in TMB-H and MSI-H tumors resistant to immune checkpoint blockade, with ORRs ranging from 20.5% to 33.3%. The trial's safety profile was ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of ...

Republican state Sen. Joe Pennachio, the Jersey co-chair of Trump’s 2020 campaign, argued Trump got 700,000 more votes that ...

Market volatility surged amid trade war tensions. Consumer staples can offer stability, value, and downside protection. Click ...

Q4 2025 Earnings Call Transcript October 16, 2025 Commercial Metals Company beats earnings expectations. Reported EPS is ...

Microsoft has introduced a new wave of Copilot features on Windows 11, including Copilot Voice, Copilot Vision, and Copilot Actions, transforming every PC into a secure, AI-powered productivity ...

This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit ...

SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced ...

Abstract Number: 4351248 Title: A Phase 1b, Double-Blind, Placebo-Controlled Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Nondialysis-Dependent CKD and Anemia Date / Time: ...

The company also announced upcoming presentations at the American Society of Nephrology (ASN) Kidney Week 2025, November 6-9 in Houston, Texas highlighting data from more patients with longer duration ...